Key Points:

• Left ventricular thrombus (LVT) is a serious complication following heart attacks, particularly STEMIs, and can lead to systemic embolism or stroke.
• Warfarin has traditionally been the recommended therapy for treating LVT in patients post-STEMI.
• The RIVAWAR trial demonstrated that rivaroxaban was comparable to warfarin in achieving clot resolution at three months, providing a safer, more convenient alternative without the need for regular blood tests.

Continue reading →